Work

Supplementary Table 1 from A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma

Year: 2023

Type: supplementary-materials

Abstract: CD4 Count at baseline and after 6 cycles of combination therapy. . * For all patients, those in cohort 1 and 2, P values test the equality of the matched pair of CD4 counts from baseline to 6 cycles using Wilcoxon signed rank tests. All other P values denote comparison of the change in CD4 count from baseline to 6 cycles in responders as compared with non-responders using Wilcoxon rank sum tests.

DOI: 10.1158/1078-0432.22471602

Authors: Ramya Ramaswami, Thomas S. Uldrick, Mark N. Polizzotto, Kathleen M. Wyvill, Priscila Goncalves, Anaida Widell, Kathryn Lurain, Seth M. Steinberg, William Douglas Figg, Giovanna Tosato, Denise Whitby, Robert Yarchoan

Language: English

Topic: Viral-associated cancers and disorders

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362406167

Cites:

Cited by:

Related to: 10